Background: Inflammatory bowel disease (IBD) represents significant health challenges on a global scale, primarily encompassing Crohn’s disease and ulcerative colitis. These conditions are characterized by cycles of relapse and remission. Current treatment options, including conventional chemical therapies and biologics such as anti-Tumor Necrosis Factor α (anti-TNFα), anti-integrin, anti-interleukins 12 (IL-12) or 23 (IL-23) agents, Janus Kinase (JAK) inhibitors, and sphingosine-1-phosphate (S1p) receptor modulators, provide symptomatic relief but do not offer a cure. These therapies are associated with both localized and systemic adverse effects, necessitating careful patient monitoring. Probiotics and prebiotics have been investigated for their potential to enhance gut microbiota diversity, which may assist in managing IBD. However, their efficacy in preventing disease flares remains limited. Recent advances in drug delivery systems, including pressure-based and pH-sensitive formulations, aim at enhancing localized treatment efficacy while minimizing adverse effects. Additionally, a pharmacogenomic approach could improve treatment personalization, optimize therapeutic outcomes, and enhance patients’ quality of life by addressing mental health needs and ensuring comprehensive follow-up care. Despite increased awareness and education among healthcare providers regarding IBD, there is still a need for clearer guidance on available treatment options. Objective: This review aims at providing deeper understanding of IBD management strategies, ultimately striving to improve the quality of care for individuals affected by this disease.

Background: Multiple sclerosis is a multifactorial neurodegenerative disease characterized by autoimmune and inflammatory processes. Despite advancements in disease-modifying therapies, multiple sclerosis remains challenging due to its complex pathophysiology and variable clinical presentation. Current therapies focus on managing inflammation and promoting immunosuppression but do not achieve complete symptom regression or enhance remyelination. Emerging therapies, such as Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonists and Bruton tyrosine kinase (BTK) inhibitors, show promise in modulating inflammation and targeting immune cells. Innovative approaches like human fetal neural precursor cells (hfPNCs) and mesenchymal stem cell transplantation are being explored to reduce neural inflammation and improve neuroprotection. Early diagnosis and intervention are crucial for managing multiple sclerosis effectively and preventing progression to severe forms and permanent disability. Therapeutic education for individuals with multiple sclerosis and their caregivers is essential, emphasizing the need for clear, reliable information to support disease management and improve quality of life. Objectives: This review provides an up-to-date overview of multiple sclerosis pathophysiology, current treatments, and emerging therapies, aiming to enhance the knowledge base of healthcare professionals and researchers, facilitating informed decision-making and contributing to ongoing research efforts.